Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Nichole Adler"'
Autor:
Jennifer R. Diamond, Natalie J. Serkova, Colin D. Weekes, Bradley R. Corr, S. Lindsey Davis, Cindy L. O'Bryant, Wells A. Messersmith, Kyrie L. Dailey, Nichole Adler, Anna Capasso, Christopher H. Lieu, Todd M. Pitts, Daniel L. Gustafson, John J. Tentler, Elaine T. Lam, S. Gail Eckhardt, Ashley Glode, Stephen Leong
Publikováno v:
Molecular Cancer Therapeutics. 17:A083-A083
Background: MLN0128 is an oral inhibitor of mTOR kinase and mTORC1/2 signaling. Alisertib is an oral inhibitor of Aurora A kinase. Senescence and upregulation of genes in the PI3K/AKT/mTor pathway have been observed in triple-negative breast cancer (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba86bcd4c491efc092edd72702adb142
https://doi.org/10.1158/1535-7163.targ-17-a083
https://doi.org/10.1158/1535-7163.targ-17-a083
Autor:
Nichole Adler, Yonghua Ling, Jonathan A. Gutman, Amy J. Johnson, John C. Byrd, Daniel A. Pollyea, Pamela J. Harris, Lia Gore, Hao Li, Steven Coutre, Mitch A. Phelps
Publikováno v:
Blood. 124:1987-1987
Introduction: Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is dependent upon dysregulated signaling through the B-cell receptor (BCR) pathway. Bruton’s tyrosine kinase (BTK) mediates BCR signaling, and inhibition of BTK with ib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::58f231c2c089040910183dabcdaf78cb
https://doi.org/10.1182/blood.v124.21.1987.1987
https://doi.org/10.1182/blood.v124.21.1987.1987